Simeng Suy
Overview
Explore the profile of Simeng Suy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kearney T, Nagel L, Bourne M, Zwart A, Kumar D, Danner M, et al.
Cureus
. 2025 Feb;
17(1):e77964.
PMID: 39996202
Purpose: 18F-fluciclovine is a radiolabeled amino acid analog that is preferentially taken up by prostate cancer cells. 18F-fluciclovine PET/CT scans are approved for the detection of biochemically recurrent prostate cancer....
2.
Bhatnagar A, Marin M, Lischalk J, Koh M, Agazzi S, Suy S, et al.
Front Oncol
. 2025 Feb;
15:1519445.
PMID: 39968072
Objective: Nonfunctioning macroadenoma is a commonly diagnosed pituitary tumor. Resection is the favored treatment, with radiosurgery often utilized for residual or progressing disease. Long-term outcomes are established in the literature...
3.
Gaudian K, Koh M, Koh M, Collins R, Eden S, Zwart Z, et al.
Front Oncol
. 2025 Feb;
15:1540482.
PMID: 39949742
Introduction: Injectable GnRH receptor agonists have been shown to improve cancer control when combined with radiotherapy (RT). Relugolix is an oral GnRH receptor antagonist that achieves rapid testosterone suppression. Non-adherence...
4.
Koh M, Koh M, Hsueh J, Gallagher L, Danner M, Zwart A, et al.
Front Oncol
. 2025 Feb;
14:1496646.
PMID: 39896185
Introduction: Studies have demonstrated that injectable GnRH receptor agonists further suppress cancer progression when paired with radiotherapy (RT) in patients with intermediate- to high-risk prostate adenocarcinoma. Relugolix is a newly...
5.
Gaudian K, Koh M, Koh M, Jermain P, Khan I, Kallam D, et al.
Front Oncol
. 2024 Dec;
14:1459732.
PMID: 39640284
Introduction: Prior studies suggest lymphopenia following radiation therapy may impact toxicity and cancer control. Chronic radiation-related lymphopenia (RRL) has been noted in prostate cancer patients treated with conventionally fractionated pelvic...
6.
Koh M, Pilkington P, Koh M, Lawlor M, Creswell M, OConnor T, et al.
Front Oncol
. 2024 Nov;
14:1434504.
PMID: 39484030
Purpose: Following treatment for localized prostate cancer, a subset of men will develop recurrent disease in the abdominopelvic nodes. For radiation therapy (RT), the optimal treatment volume, fractionation schedule, and...
7.
Hsueh J, Gallagher L, Koh M, Shah S, Danner M, Zwart A, et al.
Front Oncol
. 2024 Aug;
14:1412786.
PMID: 39188681
Introduction: Androgen deprivation therapy has been shown to improve cancer control when combined with radiotherapy. Relugolix is an oral GnRH receptor antagonist that achieves rapid profound testosterone suppression, which may...
8.
Ching L, Bourne M, Kearney T, Choudhury K, Zwart A, Danner M, et al.
Cureus
. 2024 Jul;
16(6):e63105.
PMID: 39055460
Prostate-specific membrane antigen (PSMA) imaging has become a mainstay diagnostic tool in staging unfavorable primary prostate cancer (PC) and identifying sites of recurrence in previously treated PC. One of the...
9.
Shah S, Saravanakumar S, Conroy D, Sowmiyanarayanan S, Singh R, Pepin A, et al.
Cureus
. 2024 Jul;
16(5):e61432.
PMID: 38947568
Purpose: Stereotactic body radiation therapy (SBRT) has been established as a safe and effective treatment for prostate cancer. SBRT requires high accuracy to reduce treatment margins. Metal hip prostheses create...
10.
Hsueh J, Gallagher L, Koh M, Eden S, Shah S, Wells M, et al.
Front Oncol
. 2024 Apr;
14:1377103.
PMID: 38665954
Introduction: Sexual function following local treatment for prostate cancer is an important quality of life concern. Relugolix is a novel oral GnRH receptor antagonist used in combination with radiation therapy...